In this episode, Sidney Ocanagil-Tunstall is joined by Dr Asif Naseem, GP and specialist in preventative healthcare and men’s health, alongside Dr Beat Rheiner, CEO of Proteomedix. Together, they discuss the role of PSA testing in current prostate cancer pathways, why many patients fall into a diagnostic “gray zone,” and how emerging approaches could improve early detection and reduce uncertainty for both clinicians and patients.

The conversation explores the importance of personalised risk assessment, the impact of false positives and false negatives, and how new diagnostic tools may help identify clinically significant cancers earlier while supporting more efficient, patient-centred care.